Manufacturing Miracles
LATEST NEWS
Novavax and Catalent Biologics Enter Strategic Partnership: Allowing Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax’ Manufacturing Assets and Capabilities
GAITHERSBURG, MD, June 27, 2019 (GLOBE NEWSWIRE): Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Catalent Biologics’ Paragon Gene Therapy unit, the leading viral vector...
IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases
New York, NY and Somerset, NJ — June 17, 2019 — IVERIC bio, Inc. (NASDAQ: ISEE) and Catalent Biologics, today announced that they have entered into an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for IVERIC...
Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion
SOMERSET, N.J. – May 20, 2019 — Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion...
MEDIA & PRESS CONTACT
Colleen Floreck, Senior Director, Marketing & Communications
+1 443-262-3246 | cfloreck@paragonbioservices.com
JOIN THE CONVERSATION
Follow us on social media!
EVENTS
Come meet us!
Bioprocessing Summit
August 12 – 16
Seaport World Trade Center, Boston, MA
Booth 134
Paragon Bioservices will be attending and or be exhibiting at the following events.
Phacilitate Leaders Europe
September 17 – 18
Royal Lancaster, London
Paragon Bioservices will be attending and or be exhibiting at the following events.
Cell & Gene Meeting on the Mesa
October 2 – 4
Carlsbad, CA